109 related articles for article (PubMed ID: 7691898)
21. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
[TBL] [Abstract][Full Text] [Related]
22. On the mechanism of radiation-induced emesis: the role of serotonin.
Scarantino CW; Ornitz RD; Hoffman LG; Anderson RF
Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):825-30. PubMed ID: 7525517
[TBL] [Abstract][Full Text] [Related]
23. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
[TBL] [Abstract][Full Text] [Related]
24. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
[TBL] [Abstract][Full Text] [Related]
25. Drug treatment of chemotherapy-induced delayed emesis.
Tavorath R; Hesketh PJ
Drugs; 1996 Nov; 52(5):639-48. PubMed ID: 9118814
[TBL] [Abstract][Full Text] [Related]
26. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy.
Cubeddu LX; O'Connor DT; Parmer RJ
J Clin Oncol; 1995 Mar; 13(3):681-7. PubMed ID: 7533826
[TBL] [Abstract][Full Text] [Related]
27. A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimen.
Findlay M; Simes RJ; Cox K; Carmichael K; Chey T; McNeil E; Raghavan D
Eur J Cancer; 1993; 29A(3):309-15. PubMed ID: 8398324
[TBL] [Abstract][Full Text] [Related]
28. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
29. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients.
Alfieri AB; Cubeddu LX
Br J Cancer; 1995 Mar; 71(3):629-32. PubMed ID: 7533519
[TBL] [Abstract][Full Text] [Related]
30. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies.
Cubeddu LX; O'Connor DT; Hoffmann I; Parmer RJ
Br J Cancer; 1995 Oct; 72(4):1033-8. PubMed ID: 7547218
[TBL] [Abstract][Full Text] [Related]
31. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.
Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tamura T; Fujiwara Y; Mae M; Fukuda M; Ohe Y; Sasaki S
Jpn J Clin Oncol; 1989 Mar; 19(1):40-4. PubMed ID: 2921817
[TBL] [Abstract][Full Text] [Related]
32. Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy.
Janes RJ; Muhonen T; Karjalainen UP; Wiklund T
Eur J Cancer; 1998 Jan; 34(1):196-8. PubMed ID: 9624258
[TBL] [Abstract][Full Text] [Related]
33. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766
[TBL] [Abstract][Full Text] [Related]
34. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
[TBL] [Abstract][Full Text] [Related]
36. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Higa GM; Auber ML; Altaha R; Piktel D; Kurian S; Hobbs G; Landreth K
J Oncol Pharm Pract; 2006 Dec; 12(4):201-9. PubMed ID: 17156592
[TBL] [Abstract][Full Text] [Related]
37. Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy.
Catalán Arlandis JL; Jiménez Torres NV
Ann Pharmacother; 2000 May; 34(5):573-9. PubMed ID: 10852082
[TBL] [Abstract][Full Text] [Related]
38. Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer.
Passalacqua R; Cocconi G; Caminiti C; Silingardi V; Bella MA; Bichisao E; Michiara M; Malavasi V; Donati D; Di Costanzo F; Rocca A; Di Sarra S; Scaglione F; Fraschini F
J Clin Oncol; 1997 Jun; 15(6):2467-73. PubMed ID: 9196163
[TBL] [Abstract][Full Text] [Related]
39. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial.
Kris MG; Gralla RJ; Clark RA; Tyson LB; Groshen S
Cancer; 1987 Dec; 60(11):2816-22. PubMed ID: 3315176
[TBL] [Abstract][Full Text] [Related]
40. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]